Abstract | BACKGROUND: This study aimed to investigate the effect of intensive patient's care program ( IPCP) on anxiety, depression and survival profiles in de novo acute myelocytic leukemia (AML) patients receiving chemotherapy. METHODS: A total of 220 de novo AML patients underwent chemotherapy were randomly allocated to IPCP or control group as 1:1 ratio. In the randomized-controlled stage, IPCP group received IPCP and usual care for 12 months while control group only received usual care. Anxiety and depression were assessed by Hospital Anxiety and Depression Scale ( HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS). Patients were followed up in the long-term follow-up stage (median: 20.0 months), and event-free survival (EFS) and overall survival (OS) were calculated. RESULTS:
HADS-Anxiety ( HADS-A) score, anxiety rate and anxiety severity were deceased at M12, and HADS-A score change (M12-M0) was larger in IPCP group compared with control group. Meanwhile, SAS score at M6, M9 and M12 were reduced in IPCP group compared to control group. Regarding depression, HADS-Depression ( HADS-D) score at M12 was lower, and HADS-D/SDS score change (M12-M0) was greater in IPCP group compared with control group. Additionally, IPCP group illustrated a prolonged OS compared to control group, and patients with sustained depression by HADS-D/SDS score disclosed a worse OS compared with non-sustained depression patients. CONCLUSIONS: In conclusion, IPCP decreases anxiety and depression as well as improves OS in de novo AML patients receiving chemotherapy.
|
Authors | Hongxia Bao, Yalin Chen, Min Li, Longrui Pan, Xuena Zheng |
Journal | Translational cancer research
(Transl Cancer Res)
Vol. 8
Issue 1
Pg. 212-227
(Feb 2019)
ISSN: 2219-6803 [Electronic] China |
PMID | 35116750
(Publication Type: Journal Article)
|
Copyright | 2019 Translational Cancer Research. All rights reserved. |